International Cannabinoid Research Society

Strainsforpains CEO Simon Shainberg Discusses Entering 191 Billion Dollar Anti-Inflammatory Market, and Strategic Partnership and Research Potential with GenBio Corp.

Retrieved on: 
Thursday, March 14, 2024
Toxicity, Health, Longevity, Drug discovery, Science, Media, Partnership, Education, Patient, Research, Security (finance), Investigational New Drug, OTC, Catalog, Immune system, International Cannabinoid Research Society, Nursing, Pharmaceutical industry

Strainsforpains is also progressing towards its change of symbol on the OTC Markets, with its upcoming audited financials within 2024.

Key Points: 
  • Strainsforpains is also progressing towards its change of symbol on the OTC Markets, with its upcoming audited financials within 2024.
  • In Australia, there are natural extracts that demonstrate outstanding potential in the medical and health field.
  • GenBio has reviewed numerous natural extracts over the last five years.
  • GenBio’s current research program is a potentially powerful anti-inflammatory drug program with lower toxicity than existing pharmaceutical drugs.

StrainsForPains, Inc. Discusses Inspiration, App Technology and CBD Market Entrance with The Stock Day Podcast

Retrieved on: 
Thursday, February 29, 2024
Pet, Anxiety, Parkinson's disease, Intelligence, Traction, Chemical oxygen demand, DSM-IV codes, Quality of life, Cancer, MIT, Pain, OTC Markets Group, State, Database, Cannabinoid, State university system, International Cannabinoid Research Society, Chronic pain, Business, SUNY, Depression, CBD, Patient, Medicine, Osteoarthritis, Pharmacotherapy, Movement, Interview, Insomnia, Cannabis, Research, Alzheimer's disease

I financed and worked with Olivia Newton-John's Koala Blue in the 1980's and Richard Diehl's Graphsoft (now Vectorworks) in the 1990's.

Key Points: 
  • I financed and worked with Olivia Newton-John's Koala Blue in the 1980's and Richard Diehl's Graphsoft (now Vectorworks) in the 1990's.
  • I developed regenerative medicine systems with stem cell technology in the 1980's working on umbilical cord therapy to treat genetic diseases, cancers, and inherited disorders.
  • In 2024 we will focus our efforts on the development of our upcoming advanced AI app and our CBD brand that will expand into many products.
  • We will seek to forge a new path in our approach to healthcare, that will expand to CBD products for pets as well as a nutritional app.

Strainsforpains, Inc. Investors Update: Strainsforpains, Inc. Showing Strong Revenue Growth

Retrieved on: 
Thursday, March 7, 2024
Acquisition, Hospital, Media, Nano, Intelligence, Absorption, Tri, Farmer, Housing, Growth, Pharmacy, Health, Bay Parkway, International Cannabinoid Research Society, Pain management, Nursing, Patient, Security (finance), Housing Works

The initial order, comprising over 3000 units of CBD body cream, is set to be distributed across pharmacies and wellness centers in the Tri State area.

Key Points: 
  • The initial order, comprising over 3000 units of CBD body cream, is set to be distributed across pharmacies and wellness centers in the Tri State area.
  • The positive responses from stores, dispensaries and customers have fueled our determination to diversify our CBD product line into other CBD later in 2024”.
  • Mr. Shainberg emphasized “The introduction of diversified products, coupled with strategic partnerships with hemp farmers in Virginia and Pennsylvania, positions our company for rapid growth in 2024.
  • For further info and Media Contact:
    [email protected] 347-218-0844 244 Fifth Avenue Suite S242, New York, N.Y. 10001

Strainsforpains Inc. Announces Corporate Update

Retrieved on: 
Friday, February 23, 2024
Hospital, Media, Intelligence, Absorption, Growth, International Cannabinoid Research Society, Pain management, Nursing, Patient, Security (finance), Glaucoma, Research

Strainsforpains is pleased to announce that it has increased the capacity of its Pennsylvania facility to accommodate the company’s growing CBD product line.

Key Points: 
  • Strainsforpains is pleased to announce that it has increased the capacity of its Pennsylvania facility to accommodate the company’s growing CBD product line.
  • Based on updated preliminary orders, Strainsforpains foresees CBD sales exceeding $500,000 for fiscal 2024.
  • Strainsforpains, Inc. is an innovative healthcare data technology Company located in New York, N.Y.
  • Although Strainsforpains, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Strainsforpains, Inc. is unable to give any assurance that its expectations will be attained.

Strainsforpains, Inc. secures its largest orders to date from NYC establishments

Retrieved on: 
Friday, January 19, 2024
Patient, Hospital, Pain management, Force of nature, Nursing, International Cannabinoid Research Society, Absorption, Myalgia, Security (finance), Media, Physician, 3D printing

Strainsforpains, Inc. is pleased to announce it has closed out 2023 with its largest orders to date, valued at $65,000, from various CBD and health markets, including Forces of Nature, Portokali, and other prominent establishments in New York City.

Key Points: 
  • Strainsforpains, Inc. is pleased to announce it has closed out 2023 with its largest orders to date, valued at $65,000, from various CBD and health markets, including Forces of Nature, Portokali, and other prominent establishments in New York City.
  • This significant achievement marks a major milestone for our company and underscores the increasing demand for Strainsforpains’ high-quality products.
  • With this significant order, Strainsforpains will deliver its full spectrum topical CBD products, renowned for their exceptional quality and effectiveness.
  • The company continues its collaboration with Popped, a NYC company, to jointly develop products and services with anticipated sales of six hundred thousand dollars by the end of 2024.

Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium

Retrieved on: 
Wednesday, June 28, 2023
Texas Tech University Health Sciences Center, Therapy, Doctor of Philosophy, Associate professor, Anxiety, Research fellow, Stony Brook University, ICRS, Research, Assistant, Pain, Biochemistry, Cell biology, International Cannabinoid Research Society, CBD, Pharmaceutical industry, Anesthesiology, Cancer, Chronic pain, Neuroscience, Pharmacology

SOLANA BEACH, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its continued sponsorship of The William A. Devane Early Career Investigator Award at the 33rd International Cannabinoid Research Society (ICRS) Symposium in Toronto, Ontario, Canada.

Key Points: 
  • SOLANA BEACH, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its continued sponsorship of The William A. Devane Early Career Investigator Award at the 33rd International Cannabinoid Research Society (ICRS) Symposium in Toronto, Ontario, Canada.
  • Artelo congratulates the 2023 recipient of The William A. Devane Early Career Investigator Award Josée Guindon, Ph.D., Associate Professor, Department of Pharmacology and Neurosciences, at Texas Tech University Health Sciences Center.
  • “We are extremely pleased to be an integral part of the annual ICRS symposia as the sponsor of The William A. Devane Early Career Investigator Award for the past five years," said Gregory Gorgas, Chief Executive Officer of Artelo.
  • “We look forward to collaborating with additional top tier researchers recognized at the ICRS as we advance our novel product candidates,” continued Mr. Gorgas.

Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium

Retrieved on: 
Tuesday, June 27, 2023
Diabetic neuropathy, Chemotherapy-induced peripheral neuropathy, FABP5, The Fear Is Excruciating, but Therein Lies the Answer, Diabetes, Allodynia, Cancer, National Center for Advancing Translational Sciences, Paclitaxel, ICRS, CIPN, Pain, Patient, International Cannabinoid Research Society, Neuropathic pain, FDA, Pharmaceutical industry

SOLANA BEACH, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented preclinical data related to ART26.12, Artelo’s novel fatty acid binding protein 5 (FABP5) inhibitor at the 33rd International Cannabinoid Research Society (ICRS) Symposium in Toronto, Ontario, Canada.

Key Points: 
  • There are very limited therapeutic options currently available and these existing treatments are often associated with a significant and undesirable side effect profile.
  • According to Coherent Market Insights , the global neuropathic pain market is estimated to be valued at $7.6 billion.
  • “ART26.12 continues to demonstrate a positive effect in numerous animal models of painful neuropathies, specifically chemotherapy-induced peripheral neuropathy (CIPN) and diabetic neuropathy,” said Professor O’Sullivan.
  • Based on these results, we are highly encouraged by the potential of ART26.12 for the countless patients suffering from this often excruciating and debilitating condition.”

Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium

Retrieved on: 
Monday, June 26, 2023
Cognition, University, Depression, Anxiety, Cancer, National Center for Advancing Translational Sciences, ICRS, Research, Solubility, Social, Pain, Plasma, Patient, International Cannabinoid Research Society, Laboratory, PTSD, Pharmaceutical industry, CBD

SOLANA BEACH, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented important new data from multiple preclinical studies regarding ART12.11, Artelo’s patented cannabidiol (CBD) cocrystal, on Sunday, June 25th, at the 33rd International Cannabinoid Research Society (ICRS) Symposium in Toronto, Ontario, Canada.

Key Points: 
  • "We are delighted to have the opportunity to disclose new, and potentially groundbreaking research findings from our ongoing, preclinical development program with ART12.11, which demonstrate improved bioavailability and efficacy in nonclinical models of stress-induced anxiety versus CBD,” said Gregory D. Gorgas, President and Chief Executive Officer of Artelo.
  • These latest results provide us further confidence of the potential of ART12.11 to improve outcomes, especially for people suffering from anxiety disorders and the complications of PTSD.
  • Looking ahead, our proprietary CBD cocrystal will be a key element of our overarching strategy to introduce innovative, patented and differentiated therapeutic solutions into clinical practice for patients facing significant unmet needs."
  • “In Dr. Laviolette’s behavioral research, ART12.11 outperformed CBD dosed at three times the amount of CBD contained in our cocrystal composition,” added Professor O’Sullivan.

Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium

Retrieved on: 
Wednesday, June 7, 2023
Toronto Eaton Centre, Patent, University, Depression, Therapy, Eaton Centre, Anxiety, Cancer, JW Marriott Downtown Houston, Pharmacokinetics, National Center for Advancing Translational Sciences, ICRS, Research, Pain, Professor, Patient, International Cannabinoid Research Society, Pharmaceutical industry, CBD

Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, is scheduled to present new data on ART12.11, Artelo’s patented cannabidiol cocrystal, at the ICRS on Sunday, June 25th at 9:15 EDT.

Key Points: 
  • Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, is scheduled to present new data on ART12.11, Artelo’s patented cannabidiol cocrystal, at the ICRS on Sunday, June 25th at 9:15 EDT.
  • The medicinal potential of CBD has been established; however, because it is poorly absorbed there have been challenges related to the oral administration of CBD.
  • Cocrystals are solid compositions designed to improve the physical characteristics of a drug, which can produce pharmaceutical, regulatory, and manufacturing advantages.
  • “We are excited to share new, positive research results from our ongoing preclinical development program with ART12.11,” said Gregory D. Gorgas, President and Chief Executive Officer at Artelo.

Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam

Retrieved on: 
Monday, May 8, 2023
Obesity, CSE, Hebrew University of Jerusalem, Therapy, Metabolism, Weight loss, Harvey, Al-Quds, Coronavirus Scientific Advisory Board, Nanotechnology, FSE, IP, Cannabinoid, National Institute on Alcohol Abuse and Alcoholism, DSM-IV codes, International Cannabinoid Research Society, Patient, CWY, NIH, NIAAA, Pharmaceutical industry, Alcoholism

Tel Aviv, Israel / Vancouver, Canada, May 08, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has appointed Professor Joseph (Yossi) Tam, D.M.D., Ph.D., to its Scientific Advisory Board (“SAB”). Prof. Tam is the Head of the Obesity and Metabolism Laboratory and the Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem.

Key Points: 
  • Tel Aviv, Israel / Vancouver, Canada, May 08, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has appointed Professor Joseph (Yossi) Tam, D.M.D., Ph.D., to its Scientific Advisory Board (“SAB”).
  • Prof. Tam is the Head of the Obesity and Metabolism Laboratory and the Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem.
  • “I believe in the power of collaboration to bring innovative solutions to major health challenges,” said Prof. Tam.
  • “By joining Clearmind Medicine’s Scientific Advisory Board, I look forward to carrying out significant strides in the discovery and development of novel psychedelic-derived therapeutics for obesity and metabolic disorders.”